VIRX
Viracta Therapeutics Inc
Price:  
0.08 
USD
Volume:  
9,368,752.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

VIRX WACC - Weighted Average Cost of Capital

The WACC of Viracta Therapeutics Inc (VIRX) is 5.0%.

The Cost of Equity of Viracta Therapeutics Inc (VIRX) is 54.45%.
The Cost of Debt of Viracta Therapeutics Inc (VIRX) is 5.00%.

Range Selected
Cost of equity 30.70% - 78.20% 54.45%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 4.4% - 5.6% 5.0%
WACC

VIRX WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 5.83 13.1
Additional risk adjustments 0.0% 0.5%
Cost of equity 30.70% 78.20%
Tax rate 26.20% 27.00%
Debt/Equity ratio 37.74 37.74
Cost of debt 5.00% 5.00%
After-tax WACC 4.4% 5.6%
Selected WACC 5.0%

VIRX's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for VIRX:

cost_of_equity (54.45%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (5.83) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.